News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astex Pharmaceuticals (ASTX) Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients


9/10/2012 9:11:27 AM

DUBLIN, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a clinical trial with HSP90 inhibitor AT13387 in prostate cancer patients. The AT13387-04 study is a Phase 1-2, open label, randomized study in patients with castration-resistant prostate cancer (CRPC) who are no longer responding to treatment with standard of care therapies abiraterone acetate and steroids. CRPC patients who do not respond to abiraterone acetate and steroids currently have limited treatment options.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES